Search

03/11/2025 First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO)
Ubieto, AJ, Alós, DG, Dominguez, SR, Magnano, L, Sánchez, S, Vicente, FD, Iacoboni, G, Losada, CM, Manso, RG, Browne, S, Izquierdo, AR, Baumann, T, Bacelar, AG, Santaella, MP, Prieto, PG, De Villambrosia, SG, Bastos-Oreiro, M, Hernandez, AC, De Miguel, LB, Sturla, AL, Abellan, PF, Vidaller, PJP, Amutio, E, Toimil, FS, Pardal, E, Micó, M, Prat, AM, De La Cruz, B, Huerga, S, Landwehr, M, Hernández, I, Andreu, R, De la Cruz, J, Barca, EG. First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO). BLOOD. 2025; 146DOI:10.1182/blood-2025-3677. PMID:. IF:23.100(Q1/1D).
03/11/2025 Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)
Gurnari, C, Ottone, T, Piciocchi, A, Späth, D, Meid, A, Marsili, G, Fabiani, E, Romano, F, Pascale, MR, Chiusolo, P, Di Ianni, M, Sobas, M, Brunetti, L, Oñate, G, Infante, JB, Nanni, J, Vetro, C, Boada, M, Candoni, A, Sierra, J, Potter, N, Gilkes, A, Johnson, S, Thomas, I, Huntley, B, Russell, N, Dillon, R, Döhner, H, Döhner, K, Voso, MT. Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG). BLOOD. 2025; 146DOI:10.1182/blood-2025-217. PMID:. IF:23.100(Q1/1D).
03/11/2025 First worldwide real-life data on fixed-duration ibrutinib plus venetoclax treatment for previously untreated CLL/SLL patients: Updated interim analysis of Spain's LI plus VE observational study
Hernández-Rivas, JA, Prat, AM, Ponce, ES, Medina, A, Lluch-García, R, Oliveira, ACD, Rodriguez-Fernandez, A, Soler, JA, Terol-Castera, MJ, Machado-Machado, P, Pérez-Encinas, M, Romero-Carmona, R, Segundo, LYS, García-Martin, P, Mompo, C, Zubillaga-Marban, E. First worldwide real-life data on fixed-duration ibrutinib plus venetoclax treatment for previously untreated CLL/SLL patients: Updated interim analysis of Spain's LI plus VE observational study. BLOOD. 2025; 146DOI:10.1182/blood-2025-2728. PMID:. IF:23.100(Q1/1D).
03/11/2025 Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study
Niebla, AM, Gine, E, Bastos-Oreiro, M, Perez, A, Cabirta, A, Vicente, FD, Vilaseca, MC, Ubieto, AJ, De Villambrosia, SG, Prat, AM, Barca, EG, Henriquez, HDL, Herranz, ER, Prieto, PG, Cordoba, R, Carreres, AS, Garcia-Sancho, AM, Moya, AMGN, Grande, C, Martine, PP, Nicolas, C, Gutierrez, A, Rivas, JAH, Sanchez-Gonzalez, B, Villalobos, MT, Garcia-Cerecedo, T, Trillo, RA, Donato, E, Gutierrez, PV, Belmonte, DG, Cozzarelli, SRV, Ordoñez, SS, De La Mano, EP, Avaría, A, Blanco, LV, Roldan-Perez, A, Sancho, JM, De la Cruz, B, Prince-Eladnani, R, Abrisqueta, P. Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study. BLOOD. 2025; 146DOI:10.1182/blood-2025-3592. PMID:. IF:23.100(Q1/1D).